LeMaitre Vascular Inc (LMAT) Given Consensus Recommendation of “Hold” by Analysts

LeMaitre Vascular Inc (NASDAQ:LMAT) has received an average rating of “Hold” from the eight research firms that are currently covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $31.33.

Several equities research analysts have recently weighed in on the stock. Canaccord Genuity reduced their target price on shares of LeMaitre Vascular from $30.00 to $29.00 and set a “hold” rating on the stock in a research note on Friday, October 27th. Zacks Investment Research raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a research note on Tuesday, October 31st. First Analysis downgraded shares of LeMaitre Vascular from an “overweight” rating to an “equal weight” rating and set a $34.00 target price on the stock. in a research note on Friday, October 27th. Benchmark downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, October 27th. Finally, BidaskClub downgraded shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Saturday, December 2nd.

Shares of LeMaitre Vascular (NASDAQ LMAT) opened at $35.17 on Friday. LeMaitre Vascular has a 12 month low of $19.82 and a 12 month high of $39.88. The firm has a market cap of $680.63, a price-to-earnings ratio of 45.68, a PEG ratio of 2.72 and a beta of 0.53.

In related news, insider David B. Roberts sold 4,123 shares of the firm’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $32.14, for a total value of $132,513.22. Following the transaction, the insider now owns 24,482 shares of the company’s stock, valued at approximately $786,851.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 23.70% of the company’s stock.

A number of hedge funds have recently bought and sold shares of LMAT. Conestoga Capital Advisors LLC increased its stake in LeMaitre Vascular by 55.3% in the 4th quarter. Conestoga Capital Advisors LLC now owns 1,327,376 shares of the medical instruments supplier’s stock worth $42,264,000 after buying an additional 472,732 shares during the period. Vanguard Group Inc. increased its stake in LeMaitre Vascular by 23.5% in the 2nd quarter. Vanguard Group Inc. now owns 815,580 shares of the medical instruments supplier’s stock worth $25,462,000 after buying an additional 155,249 shares during the period. Janus Henderson Group PLC purchased a new position in LeMaitre Vascular in the 2nd quarter worth about $4,661,000. State Street Corp increased its stake in LeMaitre Vascular by 25.2% in the 2nd quarter. State Street Corp now owns 382,824 shares of the medical instruments supplier’s stock worth $11,951,000 after buying an additional 77,009 shares during the period. Finally, Nationwide Fund Advisors increased its stake in LeMaitre Vascular by 804.0% in the 2nd quarter. Nationwide Fund Advisors now owns 70,362 shares of the medical instruments supplier’s stock worth $2,197,000 after buying an additional 62,579 shares during the period. 71.62% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “LeMaitre Vascular Inc (LMAT) Given Consensus Recommendation of “Hold” by Analysts” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/04/lemaitre-vascular-inc-lmat-given-consensus-recommendation-of-hold-by-analysts.html.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply